The past decade has transformed liquid biopsy, which was previously just an exciting concept, into a routine, commercially viable technology that is saving patients’ lives and transforming clinical trials.
If you are working in precision oncology, or need enhanced insights into your patient population, optimized diagnostic and prognostic tools, or earlier detection of disease, this meeting should be considered a staple entry in your conference calendar. Across ctDNA, MRD, multi-omic biomarkers, and novel analytes, you will see how pharma are strategically integrating liquid biopsies into therapeutic pipelines, how diagnostic companies are designing more sensitive assays, and how the field is overcoming barriers to widespread clinical adoption.
- See the full event guide here: https://ter.li/nwkakw
- With free* tickets available for biopharma, visit the website to register: https://ter.li/2ewl2u
*Subject to terms and conditions